New Hepatitis C Study Cures 90% of Patients
Bristol-Myers hepatitis C treatment cures up to 90 percent in new study
A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.
The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol’s daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease.
Continue reading this entire article:
FREE Educational Webinar: What You Need to Know About HCV
Diet Supplement Tied to Hepatitis